Silicon Labs Guides Q4 Well Above Estimates - Quick Facts

While reporting financial results for the third quarter on Wednesday, wireless technology firm Silicon Labs Inc. (SLAB) provided earnings and revenue guidance for the fourth quarter, well above analysts' expectations.

For the fourth quarter, the company expects loss in a range of $0.41 to $0.31 per share and adjusted earnings in a range of $0.50 to $0.60 per share on revenues between $195 million and $205 million.

On average, analysts polled by Thomson Reuters expect the company to report earnings of $0.19 per share on revenues of $179.83 million for the quarter. Analysts' estimates typically exclude special items.

In connection with its previously announced $400 million share repurchase authorization, the company intends to enter into an accelerated share repurchase (ASR) agreement with an investment bank under which it will repurchase $400 million of its common stock on terms to be negotiated, subject to customary adjustments. The final settlement of the ASR is expected to be completed in the first quarter of 2022.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Rancho Cordova, California-based E-filliate Inc. is recalling about 301,800 units of DEWALT wireless earphones citing burn and fire risks, the U.S. Consumer Product Safety Commission said. The recall involves DEWALT Jobsite Pro Wireless Earphones, which have a black and yellow neckband with wired earbuds. According to the agency, the wireless earphones can overheat while charging or in use. The five-day holiday shopping period from Thanksgiving Day through Cyber Monday saw about 180 million Americans making in-store and online purchases, according to the National Retail Federation's Annual Thanksgiving Weekend Consumer Survey, conducted by Prosper Insights & Analytics. The shoppers spent an average of $301.27 on holiday-related purchases such as gifts, décor, apparel and toys. Biopharmaceutical company Immunome, Inc. (IMNM) announced Wednesday that it has conducted an assessment of the reported mutations in the new SARS-CoV-2 variant, Omicron (B.1.1.529). Based upon structural mapping of those mutations and activity against previous and current CDC variants of concern,...
Follow RTT